Cogent Biosciences, Inc.
COGT$6.08B
Mid CapNASDAQBiotechnology🇺🇸North America205 employees
Drugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Mar 15, 2027
46wMarket Overview
Stock performance and key metrics
COGT News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
CGT9486 plus sunitinib
Advanced Gastrointestinal Stromal Tumors
CGT9486
Gastrointestinal Stromal Tumors
bezuclastinib
Advanced Systemic Mastocytosis (AdvSM)
Bezuclastinib Tablets (Formulation A)
SSM
CGT4859
Intrahepatic Cholangiocarcinoma (Icc)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CGT9486 plus sunitinib | Phase 3 | Advanced Gastrointestinal Stromal Tumors | - | - |
CGT9486 | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
bezuclastinib | Phase 2 | Advanced Systemic Mastocytosis (AdvSM) | - | - |
Bezuclastinib Tablets (Formulation A) | Phase 2 | SSM | - | - |
CGT4859 | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply